Can a 'flawless' live vector vaccine strain be engineered?

Trends in Microbiology

Volumn 9, Issue 8, 2001, Pages 372-376

  Galen, James E ^a   Levine, Myron M ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LIVE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN;

BIOENGINEERING; BODY BURDEN; DNA SEQUENCE; DRUG EFFICACY; FITNESS; GENE CONTROL; GENE EXPRESSION; GENETIC CODE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; METABOLISM; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTECTION; REVIEW; SALMONELLA ENTERICA; SALMONELLA TYPHI; SALMONELLA TYPHIMURIUM; STRAIN DIFFERENCE;

ANTIGENS, BACTERIAL; BACTERIAL INFECTIONS; BACTERIAL VACCINES; GENETIC VECTORS; HUMANS; SALMONELLA TYPHI; SALMONELLA TYPHIMURIUM; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 0035422682     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-842X(01)02096-0     Document Type: Review

References (54)

1. Live oral Salmonella vaccines: Potential use of attenuated strains as carriers of heterologous antigens to the immune system
2. Attenuated Salmonella as carriers for the expression of foreign antigens
3. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens
4. Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908
5. Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine
6. Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: Development of a single-dose oral tetanus vaccine
7. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety. II. Expression in avirulent Salmonella spp. for mucosal immunization
8. Engineered ΔguaB-A, ΔvirG Shigella flexneri 2a strain CVD 1205: Construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine
9. Further characterization of ΔaroA, ΔvirG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live vector vaccine for delivering antigens of enterotoxigenic Escherichia coli
10. Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal antiamebic and anti-V. cholerae antibody responses in mice
11. Induction of cell-mediated immune responses to human immunodeficiency virus type 1 Gag protein by using Listeria monocytogenes as a live vaccine vector
12. Safety and immunogenicity of recombinant Bacille Calmette-Guerin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: A candidate Lyme disease vaccine
13. Rational live oral carrier vaccine design by mutating virulence-associated genes of Yersinia enterocolitica
14. Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization
15. Expression of the protective antigen of Bacillus anthracis by Lactobacillus casei: Towards the development of an oral vaccine against anthrax
16. Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine
17. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system
18. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers
19. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria
20. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi
21. Cytotoxic T lymphocytes after oral immunization with attenuated vaccine strains of Salmonella typhi in humans
22. IgA-driven T-cell-mediated antibacterial immunity in man after live oral Ty21 a vaccine
23. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: Strain construction and safety and immunogenicity in humans
24. Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis
25. The nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice
26. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune responses in humans
27. Phase 2 clinical trial of attenuated Salmonella enterica serovar Typhi oral live vector vaccine CVD 908-htrA in US volunteers
28. Metabolic load and heterologous gene expression
29. Bacterial fitness and plasmid loss: The importance of culture conditions and plasmid size
30. Effects of recombinant plasmid size on cellular processes in Escherichia coli
31. Host-vector interactions in Escherichia coli
32. Combining the hok/sok, parDE, and pnd postsegregational killer loci to enhance plasmid stability
33. Effects of genes exerting growth inhibition and plasmid stability on plasmid maintenance
34. Evaluation of the hok/sok killer locus for enhanced plasmid stability
35. Plasmid maintenance in Escherichia coli recombinant cultures is dramatically, steadily, and specifically influenced by features of the encoded proteins
36. Overexpression of an mRNA dependent on rare codons inhibits protein synthesis and cell growth
37. High-level expression of recombinant genes in Escherichia coli is dependent on the availability of the dnaY gene product
38. Metabolic approaches for the optimisation of recombinant fermentation processes
39. Heat-shock and stringent responses have overlapping protease activity in recombinant Escherichia coli: Implications for heterologous protein yield
40. Oral vaccination against tetanus: Comparison of the immunogenicities of Salmonella strains expressing fragment C from the nirB and htrA promoters
41. Salmonella as carriers of heterologous antigens
42. Paradigms of plasmid organization
43. Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA
44. Surface display compared to periplasmic expression of a malarial antigen in Salmonella typhimurium and its implications for immunogenicity
45. Cell surface display of human immunodeficiency virus type 1 gp120 on Escherichia coli by using ice nucleation protein
46. Surface-displayed viral antigens on Salmonella carrier vaccine
47. Delivery of epitopes by the Salmonella type III secretion system for vaccine development
48. Display of β-lactamase on the Escherichia coli surface: Outer membrane phenotypes conferred by Lpp′-OmpA′- β-lactamase fusions
49. Structural features, physiological roles, and biotechnological applications of the membrane proteases of the OmpT bacterial endopeptidase family: A micro-review
50. Processing by OmpT of fusion proteins carrying the HlyA transport signal during secretion by the Escherichia coli hemolysin transport system
51. E. coli hemolysin E (HlyE, ClyA, SheA): X-ray crystal structure of the toxin and observation of membrane pores by electron microscopy
52. Analysis of the SlyA-controlled expression, subcellular localization and pore-forming activity of a 34 kDa haemolysin (ClyA) from Escherichia coli K-12
53. Positive selection procedure for entrapment of insertion sequence elements in Gram-negative bacteria
54. Influence of vector-encoded cytokines on anti-Salmonella immunity: Divergent effects of interleukin-2 and tumor necrosis factor α